Payment overview · 2025
General Payments
$398.46
21 reported records · 12 companies
Healthcare provider profile · identity verified
Jon Mallory Mcrae, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BAINBRIDGE, GA · NPI 1700890274
Verified facts
What the public records show
CMS Open Payments records show Jon Mallory Mcrae, M.D. received $398.46 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viberzi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 408 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.84 | 16.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.82 | 16.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.48 | 15.7% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.21 | 11.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.03 | 8.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.31 | 5.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.10 | 5.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.38 | 4.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.81 | 4.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.55 | 4.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.98 | 3.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.95 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $398.46 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.82 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $63.82 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $62.48 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $47.21 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.03 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.03 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 120 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 71 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
97 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
120 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
408 | 53 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1123 | 238 |
| Levothyroxine Sodium | Levothyroxine Sodium | 869 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 723 | 169 |
| Omeprazole | Omeprazole | 714 | 152 |
| Losartan Potassium | Losartan Potassium | 658 | 146 |
| Gabapentin | Gabapentin | 573 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 519 | 130 |
| Furosemide | Furosemide | 500 | 98 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 480 | 103 |
| Alprazolam | Alprazolam | 429 | 71 |
| Eliquis | Apixaban | 408 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 380 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 374 | 83 |
| Metformin Hcl | Metformin Hcl | 364 | 89 |
| Meloxicam | Meloxicam | 361 | 92 |
| Sertraline Hcl | Sertraline Hcl | 327 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 324 | 74 |
| Tizanidine Hcl | Tizanidine Hcl | 303 | 66 |
| Lisinopril | Lisinopril | 283 | 68 |
| Carvedilol | Carvedilol | 282 | 56 |
| Tramadol Hcl | Tramadol Hcl | 282 | 78 |
| Potassium Chloride | Potassium Chloride | 275 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 246 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 237 | 60 |
| Famotidine | Famotidine | 225 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 224 | 45 |
| Simvastatin | Simvastatin | 214 | 57 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 206 | 118 |
| Pregabalin | Pregabalin | 205 | 27 |
| Prednisone | Prednisone | 192 | 92 |
| Trazodone Hcl | Trazodone Hcl | 186 | 48 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 182 | 124 |
| Clopidogrel | Clopidogrel Bisulfate | 174 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 172 | 31 |
| Warfarin Sodium | Warfarin Sodium | 169 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 166 | 31 |
| Temazepam | Temazepam | 162 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 46 |
| Aripiprazole | Aripiprazole | 156 | 24 |
| Azithromycin | Azithromycin | 156 | 111 |
| Escitalopram Oxalate | Escitalopram Oxalate | 150 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 144 | 28 |
| Atenolol | Atenolol | 140 | 33 |
| Nifedipine Er | Nifedipine | 137 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 137 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 132 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 39 |
| Ezetimibe | Ezetimibe | 128 | 38 |
| Ozempic | Semaglutide | 127 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 126 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 124 | 27 |
| Montelukast Sodium | Montelukast Sodium | 122 | 30 |
| Farxiga | Dapagliflozin Propanediol | 120 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 119 | 18 |
| Donepezil Hcl | Donepezil Hcl | 118 | 22 |
| Januvia | Sitagliptin Phosphate | 118 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 114 | 27 |
| Levofloxacin | Levofloxacin | 107 | 77 |
| Methylprednisolone | Methylprednisolone | 105 | 72 |
| Allopurinol | Allopurinol | 102 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 101 | 74 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 98 | 21 |
| Buspirone Hcl | Buspirone Hcl | 97 | 15 |
| Linzess | Linaclotide | 97 | 24 |
| Myrbetriq | Mirabegron | 97 | suppressed |
| Ondansetron Odt | Ondansetron | 96 | 34 |
| Lorazepam | Lorazepam | 92 | 16 |
| Clonazepam | Clonazepam | 89 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 19 |
| Metformin Hcl Er | Metformin Hcl | 82 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 82 | 11 |
| Celecoxib | Celecoxib | 81 | 28 |
| Meclizine Hcl | Meclizine Hcl | 81 | 41 |
| Fenofibrate | Fenofibrate Nanocrystallized | 79 | 13 |
| Spironolactone | Spironolactone | 79 | 18 |
| Mirtazapine | Mirtazapine | 78 | 17 |
| Cefuroxime | Cefuroxime Axetil | 75 | 58 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 74 | 16 |
| Levetiracetam | Levetiracetam | 73 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 13 |
| Mounjaro | Tirzepatide | 71 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 69 | 13 |
| Promethazine Hcl | Promethazine Hcl | 69 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | suppressed |
| Synthroid | Levothyroxine Sodium | 66 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 62 | suppressed |
| Trulicity | Dulaglutide | 62 | suppressed |
| Ibuprofen | Ibuprofen | 61 | 16 |
| Fluconazole | Fluconazole | 58 | 33 |
| Cephalexin | Cephalexin | 57 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 55 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 53 | suppressed |
| Chlorthalidone | Chlorthalidone | 51 | 14 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 51 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 12 |
| Cefdinir | Cefdinir | 49 | 39 |
| Baclofen | Baclofen | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 14 |
| Alendronate Sodium | Alendronate Sodium | 47 | 12 |
| Primidone | Primidone | 46 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | suppressed |
| Diazepam | Diazepam | 44 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Lovastatin | Lovastatin | 43 | 11 |
| Risperidone | Risperidone | 43 | suppressed |
| Carbamazepine | Carbamazepine | 42 | suppressed |
| Glimepiride | Glimepiride | 42 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 42 | suppressed |
| Jardiance | Empagliflozin | 41 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 40 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 39 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 39 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | 12 |
| Fentanyl | Fentanyl | 37 | suppressed |
| Hydrocortisone | Hydrocortisone | 37 | 14 |
| Labetalol Hcl | Labetalol Hcl | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | suppressed |
| Torsemide | Torsemide | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | 12 |
| Topiramate | Topiramate | 34 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Colchicine | Colchicine | 30 | 11 |
| Estradiol | Estradiol | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 15 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Anastrozole | Anastrozole | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Cilostazol | Cilostazol | 24 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Etodolac | Etodolac | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 12 |
| Ramipril | Ramipril | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Nystatin | Nystatin | 21 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Indomethacin | Indomethacin | 19 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | 12 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Effexor Xr | Venlafaxine Hcl | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Enbrel Sureclick | Etanercept | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $398.46 · 21 records | Novo Nordisk Inc | ABRYSVO, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, FARXIGA, GARDASIL 9, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error